iCamumo Biotherapeutics

Based in Suzhou, China and founded in 2021, Suzhou Aikaliyuan Biotechnology Co. , Ltd. , trading as iCamumo Biotherapeutics, is a biotechnology company mainly involved in the field of iPSC (induced pluripotent stem cells) reprogramming, gene editing, stem cell differentiation. The company built a 2,500 square meter GMP pilot plant in Suzhou and has developed multiple iPSC-CAB-NK cell therapeutic products for solid tumors in June 2021.

In March 2026, iCamumo Biotherapeutics raised over CNY 100 million in series A3 funding co-led by Voyagers Capital and InnoVision Capital, with participation from New Alliance Capital. iCamumo Biotherapeutics provides therapy drugs research and trial development, cellular technology development and application for customer, focusing on immunotherapy and regenerative medicine therapies based on its independently developed next-generation iPSC cell reprogramming platform, AI (artificial intelligence)-driven iPSC cell and organoid differentiation platform, precision gene editing platform, and advanced cell manufacturing. The company generates revenue from developing cell therapy drugs derived from iPSCs. The company will primarily use the series A3 funding to accelerate the clinical development of multiple allogeneic universal iPSC-derived cell novel drugs based on an AI-driven R&D system and the improvement of the company's strategic layout on the two major technology platforms of iPSC cell therapy and iPSC organoids.